Earlier this month the EU released the European Union Artificial Intelligence Act (The Act). #AAIHmembers Paul Howard, PhD, Senior Director of Amicus Therapeutics, Elaine H., Executive Director of the The Alliance for Artificial Intelligence in Healthcare (AAIH), Mustaqhusain Kazi Global Head of Informatics Strategy and Digital Innovation at Roche, Rafael Rosengarten Co-Founder and CEO of Genialis and James Zanewicz, JD, LLM, RTTP, Chief Business Officer at Tulane University School of Medicine, authored a response of behalf of #AAIH to the provisional agreement. This article provides valuable insights into several key aspects: the presence of bias in healthcare AI, the existing solutions addressed by the General Data Protection Regulation (GDPR), the dedication to ethically implementing AI, and the crucial role of human oversight in enhancing AI literacy. #aiinhealthcare #AI #regulation #GDPR #EU #theAct Read more in the full article here
The Alliance for Artificial Intelligence in Healthcare (AAIH)
医院和医疗保健
Baltimore，Maryland 10,189 位关注者
A global advocacy organization to enable the advancement and use of Artificial Intelligence in healthcare.
关于我们
AAIH is a global advocacy organization whose intent is to enable advancement and use of artificial intelligence in healthcare. AAIH believes that patients’ lives will be improved through investment, innovation, and the thoughtful and responsible application of AI in the discovery and development of new therapies. AAIH and its member companies and organizations are applying state‐of‐the‐art approaches and investing in advanced integrated programs (or solutions) to address society’s need for new, more effective, and accessible healthcare. The AAIH is a coalition of technology developers, pharmaceutical companies, and research organizations who have expressed the common goal of realizing the potential for AI in healthcare to significantly improve quality of care, but who also recognize that difficult questions must be considered. We are acting as a forum for these key conversations and providing a unified voice of the industry in established responsible, ethical, and reasonable standards for the development and implementation of AI in healthcare. AAIH Mandate and Goals -Develop appropriate regulations and industry guidance -Seek engagement with appropriate stakeholders -Interface with Government & NGO’s on growth of AI in healthcare industry -Stimulate data sharing and open access to key findings -Set a model and testing approach for quality control and use of standards -Establish accreditation authority and/or affiliation with academic organizations -Educate general populace, industry stakeholders, and government on value of AI and Machine Learning -Prioritize and tailor forums for regulators, payors, providers, and other end‐users as well as patients, the public, and media -Produce informative and reliable industry reports
- 网站
-
https://www.theaaih.org
The Alliance for Artificial Intelligence in Healthcare (AAIH)的外部链接
- 所属行业
- 医院和医疗保健
- 规模
- 2-10 人
- 总部
- Baltimore，Maryland
- 类型
- 非营利机构
- 创立
- 2018
- 领域
- biotechnology、pharmaceuticals、data science、technology、artificial intelligence、research、therapeutics、machine learning、precision medicine、drug discovery和ai in healthcare
地点
-
主要
获取路线
1340 Smith Ave
US，Maryland，Baltimore，21209
The Alliance for Artificial Intelligence in Healthcare (AAIH)员工
-
Ed Addison
Thought leader in AI startups, generative AI, and drug discovery. Redefining venture capital. Inspiring professor and a dynamic speaker. Twice…
-
James Zanewicz, JD, LLM, RTTP
Creativity, Connectivity & Communication in Biotech, AI & Healthcare | Moderator + Keynote Speaker + Impact & Equity Driven Partner
-
Stacie Calad-Thomson
AI in Healthcare and Life Sciences @NVIDIA | Partnering, Strategy, and Execution
-
Andrea Vuturo
Integrated Marketing & External Communications Strategist
动态
-
Exciting News from the AAIH Community! We are thrilled to highlight Altis Labs, one of our valued AAIH members, who will be presenting groundbreaking results at this week's #ELCC2025 conference in collaboration with AstraZeneca! Read the full press release here: https://lnkd.in/gHA8PCDm
?? We’re thrilled to announce the presentation of results from AstraZeneca's evaluation of our AI models at #ELCC2025! After processing the control arm imaging data from AstraZeneca’s global Phase 3 MYSTIC trial, their independent evaluation found that our AI model, IPRO-Δ, outperformed RECIST 1.1 in predicting overall survival. These findings showcase IPRO-Δ’s potential to accelerate clinical development with a stronger predictor of OS, the gold standard measure of efficacy in oncology trials. View the press release here: https://lnkd.in/gHA8PCDm
-
-
In celebration of #InternationalWomensMonth, the AAIH highlights the incredible contributions of women leading the way in AI and healthcare. Today we celebrate the incredible work of Maria Luisa Pineda, PhD. , a visionary leader and co-founder of Envisagenics, a company at the forefront of using AI to revolutionize drug discovery. Maria's work focuses on leveraging AI to uncover crucial RNA splicing errors that contribute to diseases like cancer and ALS. Through their platform, SpliceCore?, they’re speeding up the drug development process, partnering with giants like Bristol Myers Squibb and Johnson & Johnson to bring groundbreaking therapies to market faster. What excites Maria most is AI’s potential to transform the entire healthcare landscape. At Envisagenics, they’re accelerating drug discovery by slashing timelines, reducing costs, and offering targeted, personalized treatments. Looking ahead, Maria is especially excited about AI-driven advancements in personalized medicine, biomarker development, and clinical trial success. One of their proudest milestones has been developing AI algorithms that power a proprietary RNA drug target database, which has already led to successful preclinical studies and collaborations with major pharmaceutical companies. This AI-driven innovation represents a major leap forward in RNA therapeutics. In addition to her role at Envisagenics, Maria is shaping the future of AI in healthcare as a co-founder of The Alliance for Artificial Intelligence in Healthcare (AAIH) and as a member of its Board of Directors, where she is instrumental in addressing challenges like data access and building collaborations across the field. She is also passionate about mentoring the next generation of AI scientists and giving back to the community through initiatives like Life Science Cares NY. Maria’s work exemplifies how AI can drive real-world impact in healthcare, accelerating drug discovery, personalizing treatments, and improving patient outcomes!
-
-
A VERY exciting #WhatsUpWednesday this week from Luka Jelcic and DeciBio! As we step into 2025, it's the perfect moment to reflect on the evolution of AI in drug development and look ahead at its future! Luka from DeciBio just published a new white paper, "Inflection Points of Artificial Intelligence in Drug Development," exploring the key turning points in AI’s role in drug R&D. The paper dives into the dynamics shaping the field today and highlights the emerging trends that will drive the future of biopharma. Be sure to check out Luka's post below to read the full white paper - it is one you don't want to miss!
Exciting News! ? I'm thrilled to share our latest white paper, "Inflection Points of Artificial Intelligence in Drug Development," co-authored with Anastasia Christianson, Ph.D. Special thanks to Rafael Rosengarten for his valuable contributions and review! Link to get the full paper in the comments! ? As we entered 2025 we felt that it was a good time to look back at how AI use within drug development has evolved and where it is currently heading ? This paper explores the inflection points of AI use in drug R&D, highlighting key dynamics and future trends. Below are some of the analyses you can find within & attached are a few screenshots of the details: ? - Evolution of AI use in Biopharma: We track the growth and strategic shifts in the industry from early applications to current AI-first companies. We also analyze how many AI-first companies have been founded over the years - Partnership Evolution: We reviewed ~180 publicly disclosed partnerships between biopharma x AI-first players to understand how partnership volume, deal structure, and?biopharma's attitudes have changed - AI Funding Overview: We look at how funding has changed over the last 5 years and what were the key catalysts - Overview of AI-first Driven Drug Programs: We lay out the pipelines of different AI-first players across indications and stages of development to get a sense of how AI-first companies have started developing their own assets - Target Novelty Assessment: We assess the novelty of targets that select AI-first players work on based on our own grading methodology - Future Directions: We outline the potential of quantum computing to enhance AI capabilities and unlock deeper insights into complex disease biology ? Read the full paper to dive into these insights and more! As mentioned the link to the full paper is in the comments or you can message myself or Anastasia directly ? I will be at Bio-IT in Boston next - if you are attending let us meet! Anastasia will be there as well. Let's continue the conversation ? #AIinDrugDevelopment #Biopharma #Innovation #DrugDiscovery #ArtificialIntelligence #AI
-
A new week brings another chance for AAIH to celebrate the incredible women who are part of our community for #InternationalWomensMonth. Today, we're excited to spotlight DeAnn Foran Smith from Foley Hoag LLP! DeAnn Smith leads patent strategy, freedom to operate and diligence for OCMS Bio, whose proprietary platform accelerates antibody discovery and engineering utilizing AI and on-cell monoclonal antibody methods. This technology is extremely cutting edge for the biotech industry and complicated to protect due to OCMS Bio’s advanced methods, which outperform traditional antibody discovery techniques and generate antibodies having significantly improved function. Here's to DeAnn and all the trailblazing women leading innovation and breaking new ground in the AI and biotech industries! #WomeninAI #biotech #artificialintelligence
-
-
As we celebrate the achievements of remarkable women in AI this #InternationalWomensMonth, the AAIH is excited to feature Barbara Fiacco, Intellectual Property Department and Patent, Trade Secrets, and Related Rights Litigation Co- Chair at Foley Hoag LLP! Barbara recently participated in the 10th Annual Naples Roundtable Conference, where she took part in a thought-provoking panel discussion on the evolving role of artificial intelligence in patent litigation. The panel explored critical questions surrounding AI’s impact on claim construction, prior art generation, and how courts might integrate generative AI tools in patent case resolutions. The Naples Roundtable Conference brings together leading voices in intellectual property law to examine pressing issues facing the U.S. patent system, and Barbara’s expertise and leadership make her a key figure in these important discussions.
-
-
Exciting upcoming event for this week’s #WhatsUpWednesday! Join Rafael Rosengarten, AAIH Board Member and CEO of Genialis, for a fireside chat on Harnessing the Power of AI to Transform the Diagnosis and Treatment of Cancer. AI is revolutionizing the way we approach cancer, but how is it actually being applied in real-world healthcare settings? What challenges are we facing, and what incredible opportunities lie ahead? Rafael will share valuable insights on the intersection of AI and oncology! See details below!
We’ve all heard it, AI is transforming the diagnosis and treatment of cancer But how is it ???????????????? being applied in real-world settings, and what challenges and opportunities does it bring? In a fireside chat, organized by Genialis and Slovenian Technology Forum (Slovenski tehnolo?ki forum), Genialis’ co-founder and CEO Rafael Rosengarten and moderator Tjasa Zajc will talk just about that Event details:? ?? March 27, 2025, at 16.00 ?? Computer History Museum Slovenia ?? Register here: https://lnkd.in/dA6A9wTe ?Join us! Limited seats available
-
-
Continuing our celebration of #InternationalWomensMonth, we are proud to highlight the incredible women in the AAIH community! Today, we are featuring Helen Z. from Altis Labs! At Altis Labs, Helen is at the forefront of transforming oncology trials with innovative AI models that predict long-term efficacy of new drugs. These AI models are trained on over 200 million images, integrating longitudinal clinical context and survival outcomes. The result? More accurate predictions of patient outcomes, beyond simple treatment response or disease progression, enabling clinical trial sponsors to make better-informed R&D decisions while speeding up time to market. In her pivotal role, Helen drives the go-to-market strategy alongside Altis Labs CEO, while also leading the finance and operations teams. Looking to the future, Helen believes that in the next 5-10 years, AI will revolutionize clinical research. By enabling faster, smaller, and more successful clinical trials, AI will help patients access more effective treatments sooner. It will also empower clinicians with deeper insights into patient responses, enhancing care decisions. Helen’s vision and leadership are shaping the future of healthcare, and we are excited to see where it leads! #AIInHealthcare #WomenLeadership #AI #Oncology #ClinicalResearch
-
-
The Alliance for Artificial Intelligence in Healthcare (AAIH) is excited to celebrate a remarkable achievement during #InternationalWomensMonth, as AAIH Secretary and Envisagenics CEO, Maria Luisa Pineda, PhD., has been named an honoree on Inc. Magazine's 2025 #FemaleFounders500 list! This prestigious recognition highlights the most inspiring women in business, and Maria's dedication to advancing AI-driven drug discovery and fostering innovation in life sciences makes her a true leader in the field!
Envisagenics is thrilled to announce that our CEO, Maria Luisa Pineda, PhD., has been named an honoree of Inc. Magazine's 2025 #FemaleFounders500 (https://lnkd.in/ex4jJGAp)! This prestigious list recognizes the most inspiring women in business, and we couldn’t be prouder to see Maria Luisa Pineda, PhD.'s leadership and vision celebrated. Her dedication to advancing #AI-driven drug discovery and empowering innovation in #lifesciences continues to inspire us every day. Congratulations, Maria Luisa Pineda, PhD.! Read the full article here: https://lnkd.in/d_2CzDy #WomenInBio #AIinLifeSciences #HealthcareInnovation #Leadership #Envisagenics #AI #ML #ArtificialIntelligence #MachineLearning #LifeSciences?
-
-
The Alliance for Artificial Intelligence in Healthcare (AAIH) is looking forward to attending #BIOEuropeSpring, March 17–19, 2025. Let's propel the new wave of biotech innovation together! If you are attending, let us know! We would love to meet you!
-